title: Cellular therapy of cancer with natural killer cells-where do we stand?
abstract: Although T-lymphocytes have received most of the attention in immunotherapy trials, new discoveries around natural killer (NK) cells suggest that they also should be suitable effector cells for cellular therapy of cancer. In addition to direct cytotoxicity, NK cells produce an array of immune-active cytokines, among them interferons and granulocyte-macrophage colony-stimulating factor, which places them at the crossroads of innate and adaptive immunity. They also augment monoclonal antibody activity through antibody-mediated cellular cytotoxicity and can be transfected with chimeric antigen receptors. One of the stumbling blocks for NK cell-based therapies has been the inability to predictably obtain and expand larger numbers from donors, but also to achieve sufficiently high transfection efficiency of target genes. The first clinical trials with NK cells suggest some benefit, but more definite evidence is needed to justify this relatively expensive treatment.
authors.affiliation: Tufts University School of Medicine, Boston, Massachusetts, USA. hans.klingemann@tufts.edu
authors.forename: Hans G
authors.initials: HG
authors.lastname: Klingemann
mesh_terms: D000818:Animals; D049109:Cell Proliferation; D002986:Clinical Trials as Topic; D015316:Genetic Therapy; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods* / Q000639:trends; D007694:Killer Cells, Natural / Q000276:immunology / Q000637:transplantation*; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*